Overview

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
ZYIL1 is expected to show benefit in patients with Amyotrophic Lateral Sclerosis (ALS). The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with ALS.
Phase:
Phase 2
Details
Lead Sponsor:
Zydus Lifesciences Limited